About Scantox
Scantox is a Healthcare company based in Lille Skensved (Denmark) founded in 1977. Laboratory focused on providing pharmacology, toxicology, and histopathology services. The company has 30 employees. Scantox has completed 4 acquisitions, including Adlego Biomedical, Gentronix and Q&Q Labs. Scantox was last valued at $19.19 million in January 2022. Its chief executive, as recorded, is Jeanet Logsted. Its website scantox.com draws about 21 thousand monthly visits. Scantox offers products and services including Discovery Services, Genetic Toxicology Services, Regulatory Toxicology Services, and Pharmaceutical Development Services. Its focus areas include Biopharma Outsourcing, CRO and Diversified. Its legal entity is Scantox Holding Aps.
Company details
Scantox offers Discovery Services, Genetic Toxicology Services, Regulatory Toxicology Services, Pharmaceutical Development Services while focusing on providing healthcare solutions, biopharma outsourcing, cro, and diversified. Laboratory focused on providing pharmacology, toxicology, and histopathology services. Delivering reliable solutions, it emphasizes quality, efficiency, and meeting diverse client needs.
- Headquarters Lille Skensved, Denmark
- Employees 30
- Stage Minicorn
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website scantox.com
- Social LinkedIn
- Legal Name Scantox Holding Aps
- Annual Revenue$18.22 M (USD)166as on Dec 31, 2022
- Net Profit$1.16 M (USD)71as on Dec 31, 2022
- EBITDA$1.45 M (USD)282as on Dec 31, 2022
- Latest Funding Round$228.85K (USD), Unspecified
Jan 2022
- Employee Count30
- Investments & AcquisitionsAdlego Biomedical
& 3 more
Products & Services of Scantox
Scantox offers a comprehensive portfolio of products and services, including Discovery Services, Genetic Toxicology Services, Regulatory Toxicology Services, and Pharmaceutical Development Services.
Specialized services for neurology-related drug discovery and efficacy testing.
Comprehensive portfolio for genotoxicity and skin sensitization assessments.
Full spectrum of preclinical toxicology studies using various species.
Formulation development and bioanalysis for clinical trial support.
Funding Insights of Scantox
- Total Rounds 2
- Last Round Unspecified — $228,852
- First Round $6.06M
(Jan 2021)
All 2 funding rounds of Scantox with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | $228,852 | Unspecified | $19.19M | – | – |
| Jan 2021 | $6.06M | Unspecified | $6.6M | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Jan 2022 | $19.19M | •••••••• |
| Jan 2021 | $6.6M | •••••••• |
Last known valuation $19.19M (Jan 2022).
People of Scantox
57 people are tracked at Scantox (15 in leadership, 3 in board & advisors, 39 in team); the tracked headcount is 30.
| Name | Role | Group |
|---|---|---|
Jeanet Logsted | CEO | Leadership |
Ralf Rethmeier | Business Development Director DACH Benelux | Leadership |
Jeanet Løgsted | Chief Executive Officer, CEO | Leadership |
Mette Ellemann-Søtofte | COO | Leadership |
Martin Amtoft-Christensen | CFO | Leadership |
Andy Brown | Chief Commercial Officer | Leadership |
Mikkel Lykke Jensen | Chief Scientific Officer | Leadership |
Ulrika Randén | Study Director | Leadership |
Birgitte Støvring | Head Of Department Laboratories | Leadership |
Maria Korsgaard Bruhn Jensen | Study Director And Senior Veterinarian | Leadership |
Pernille Schiønning | Head Of Department Technical Operations | Leadership |
Christian Meinertz Nielsen | Head Of Information Technology | Leadership |
Sisse Ellemann-Laursen | Senior Study Director | Leadership |
Björn Platzack | Chief Operating Officer At Scantox Sweden | Leadership |
Maria Valsjö | Study Director | Leadership |
Jens Bager | Director | Board & advisors |
Daniel Spasic | Director | Board & advisors |
Nicolas Hooge | Director | Board & advisors |
Anja S. | Dyrepasser | Team |
Alexandre Chevallier | Directeur Du Développement Commercial | Team |
37 more people are available in the full profile.
Complete people profiles for Scantox
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Scantox
Scantox has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Adlego Biomedical, Gentronix and Q&Q Labs.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
In-vitro and in-vivo genetic toxicology screening services are provided. | gentronix.co.uk | Alderley Edge, United Kingdom | 1999 | Sep 2024 | •••• | |
Leading provider of preclinical services for the pharmaceutical, biotech, and medical devices industries | qandqlabs.se | Molndal, Sweden | 2010 | Aug 2023 | •••• | |
Drug R&D services for toxicology and histopathology are offered. | timeline-bioresearch.com | Lund, Sweden | 2013 | Sep 2022 | •••• | |
In-vivo pharmacology and toxicology services are provided for drug candidates. | adlego.se | Uppsala, Sweden | 2005 | Sep 2022 | •••• |
Complete acquisition details for Scantox
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Scantox
8 dated milestones of Scantox across 47 years, from founding to its latest funding, stage changes and deals.
- Founded Scantox is founded.
- Funding First funding round of $6.1M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Unspecified, of $229K.
- Acquisition Acquires Timeline Bioresearch.
- Acquisition Acquires Adlego Biomedical.
- Acquisition Acquires Q&Q Labs.
- Acquisition Acquires Gentronix.
Web traffic of Scantox
The website of Scantox (scantox.com) receives about 21.1K visits a month and ranks #1,404,357 among all websites worldwide, #1,817 in Biotechnology and Pharmaceuticals.
- Monthly visits21.1K
▲ 4.3% vs previous month
- Unique visitors8.8K
per month
- Global rank#1,404,357
among all websites
- Category rank#1,817
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit1.5
- Average visit54 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Scantox. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biotoxtech.com | 100% | 11.1K | #689,683 | View details | |
| molprofiles.co.uk | 88% | View details | |||
jrfonline.com | jrfonline.com | 88% | – | ||
snblusa.com | snblusa.com | 88% | – | ||
| iris-pharma.com | 88% | 2.2K | #10,426,473 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 32 similar websites and full traffic analytics for Scantox
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 32 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Scantox
Complete news archive for Scantox
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scantox
Scantox was founded in 1977 and raised its 1st funding round 44 years after it was founded.
Scantox is headquartered in Lille Skensved, Denmark.
Jeanet Logsted is the CEO of Scantox, as recorded in our data.
Scantox has 30 employees.
Annual revenue of Scantox is $18.22M as on Dec 31, 2022.
Scantox offers Discovery Services, Genetic Toxicology Services, Regulatory Toxicology Services, Pharmaceutical Development Services while focusing on providing healthcare solutions, biopharma outsourcing, cro, and diversified. Laboratory focused on providing pharmacology, toxicology, and histopathology services. Delivering reliable solutions, it emphasizes quality, efficiency, and meeting diverse client needs.
Scantox offers Discovery Services, Genetic Toxicology Services, Regulatory Toxicology Services, and Pharmaceutical Development Services.
Scantox has made 4 acquisitions, including Adlego Biomedical, Gentronix, and Q&Q Labs.
The valuation of Scantox is $19.19M as of Jan 2022.
Scantox operates through Scantox Holding Aps.